These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 20932071)

  • 1. Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke.
    Greer DM
    CNS Drugs; 2010 Dec; 24(12):1027-40. PubMed ID: 20932071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.
    Malloy RJ; Kanaan AO; Silva MA; Donovan JL
    Clin Ther; 2013 Oct; 35(10):1490-1500.e7. PubMed ID: 24139421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
    Jamieson DG; Parekh A; Ezekowitz MD
    J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?
    Aw D; Sharma JC
    Postgrad Med J; 2012 Jan; 88(1035):34-7. PubMed ID: 22121248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet therapy in stroke prevention: present and future.
    Caplan LR
    Cerebrovasc Dis; 2006; 21 Suppl 1():1-6. PubMed ID: 16479096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet drugs.
    Hankey GJ; Eikelboom JW
    Med J Aust; 2003 Jun; 178(11):568-74. PubMed ID: 12765506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
    Niu PP; Guo ZN; Jin H; Xing YQ; Yang Y
    BMJ Open; 2016 Mar; 6(3):e009013. PubMed ID: 26988347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility.
    Sprigg N; Gray LJ; England T; Willmot MR; Zhao L; Sare GM; Bath PM
    PLoS One; 2008 Aug; 3(8):e2852. PubMed ID: 18682741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin and clopidogrel resistance: possible mechanisms and clinical relevance. Part I: Concept of resistance.
    Vadász D; Sztriha LK; Sas K; Vecsei L
    Ideggyogy Sz; 2012 Nov; 65(11-12):377-85. PubMed ID: 23289172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke.
    Redman AR; Ryan GJ
    Expert Opin Pharmacother; 2004 Jan; 5(1):117-23. PubMed ID: 14680441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination antiplatelet agents for secondary prevention of ischemic stroke.
    Vande Griend JP; Saseen JJ
    Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet resistance in stroke.
    Topçuoglu MA; Arsava EM; Ay H
    Expert Rev Neurother; 2011 Feb; 11(2):251-63. PubMed ID: 21306212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer antiplatelet therapies in stroke prevention.
    Davis SM; Donnan GA
    Aust Fam Physician; 2001 Feb; 30(2):129-34. PubMed ID: 11280112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.
    Weber R; Diener HC
    J Cell Mol Med; 2010 Oct; 14(10):2371-80. PubMed ID: 20738445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of ischaemic stroke--antiplatelets.
    McCabe DJ; Brown MM
    Br Med Bull; 2000; 56(2):510-25. PubMed ID: 11092100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
    Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
    Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet therapy for stroke prevention.
    Hankey GJ
    Curr Atheroscler Rep; 2007 Oct; 9(4):312-8. PubMed ID: 18173959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
    Sacco RL; Diener HC; Yusuf S; Cotton D; Ounpuu S; Lawton WA; Palesch Y; Martin RH; Albers GW; Bath P; Bornstein N; Chan BP; Chen ST; Cunha L; Dahlöf B; De Keyser J; Donnan GA; Estol C; Gorelick P; Gu V; Hermansson K; Hilbrich L; Kaste M; Lu C; Machnig T; Pais P; Roberts R; Skvortsova V; Teal P; Toni D; Vandermaelen C; Voigt T; Weber M; Yoon BW;
    N Engl J Med; 2008 Sep; 359(12):1238-51. PubMed ID: 18753638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke.
    Lenz T; Wilson A
    Clin Pharmacokinet; 2003; 42(10):909-20. PubMed ID: 12885264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antiplatelet therapy of secondary stroke prevention after ESPS-2 and CAPRIE].
    Alvarez-Sabín J; Montaner-Villalonga J
    Rev Neurol; 1999 Oct 16-31; 29(8):780-4. PubMed ID: 10560115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.